Wave Life Sciences (WVE) stock plummeted 5.08% on Wednesday in the intraday trading session, despite reporting a significant revenue surge in its Q4 2024 earnings.
The biotechnology company, focused on developing RNA medicines, saw its revenue climb to $83.7 million in Q4 2024, up from the previous quarter. This was driven by recognition of deferred revenue from its collaboration with Decata. However, the company's expenses also increased substantially, raising concerns among investors.
Research and development expenses soared to $44.6 million in Q4 2024, primarily due to increased spending on Wave's INHBE, AATD, and DMD programs. General and administrative expenses also rose to $16.1 million during the same period. Despite the revenue boost, Wave Life Sciences reported a net loss of $96.7 million for the full year 2024, indicating ongoing financial challenges.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。